AR092129A1 - 2,3-benzodiazepinas como inhibidoras de proteinas bet - Google Patents
2,3-benzodiazepinas como inhibidoras de proteinas betInfo
- Publication number
- AR092129A1 AR092129A1 ARP130102888A ARP130102888A AR092129A1 AR 092129 A1 AR092129 A1 AR 092129A1 AR P130102888 A ARP130102888 A AR P130102888A AR P130102888 A ARP130102888 A AR P130102888A AR 092129 A1 AR092129 A1 AR 092129A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- amino
- halo
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen 2,3-benzodiazepinas inhibidores de proteínas BET, especialmente inhibidoras de BRD4, productos intermedios para la preparación de los compuestos según la presente, agentes farmacéuticos que contienen los compuestos, así como su uso profiláctico y terapéutico en enfermedades hiperproliferativas, especialmente en enfermedades tumorales. Además, se describe el uso de inhibidores de proteínas BET en hiperplasias benignas, enfermedades ateroscleróticas, septicemia, enfermedades autoinmunitarias, enfermedades vasculares, infecciones virales, en enfermedades neurodegenerativas, en enfermedades inflamatorias, en enfermedades ateroscleróticas y en el control de la fertilidad masculina. Reivindicación 1: Compuestos de fórmula general (1) en la que X representa un átomo de oxígeno o de azufre, y A representa un anillo de heteroarilo monocíclico con 5 ó 6 átomos de anillo o representa un anillo de fenilo, y R¹ᵃ representa hidrógeno, halógeno, ciano, carboxi, amino o aminosulfonilo, o representa un resto alcoxi C₁₋₆, alcoxi C₁₋₃-alquilo C₁₋₃, alcoxi C₁₋₃-alcoxi C₂₋₃, alquil C₁₋₆-amino, alquil C₁₋₆-carbonilamino, alquil C₁₋₆-amino-alquilo C₁₋₆, N-(heterociclil)-alquilo C₁₋₆, N-(heterociclil)-alcoxi C₁₋₆, hidroxi-alquilo C₁₋₆, hidroxi-alcoxi C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, alquil C₁₋₆-carbonilo o alcoxi C₁₋₆-carbonilo, o representa un resto heterociclilo monocíclico con 3 a 8 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, ciano, nitro, hidroxi, amino, oxo, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, hidroxialquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, alquil C₁₋₆-amino-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, cicloalquilo C₃₋₁₀, fenilo, halofenilo, fenil-alquilo C₁₋₆, piridinilo, -NR⁶C(=O)-R⁹, -C(=O)-NR⁶R⁷, -C(=O)-R⁸, -S(=O)₂-NR⁶R⁷, -S(=O)-R⁹, -S(=O)₂-R⁹, -NH-S(=O)₂-R⁹ y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representa un resto heteroarilo monocíclico con 5 ó 6 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, hidroxi, amino, ciano, nitro, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, alquil C₁₋₆-amino-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, cicloalquilo C₃₋₁₀, -C(=O)-NR⁶R⁷, -C(=O)-R⁸, -S(=O)₂-NR⁶R⁷, -S(=O)-R⁹, -S(=O)₂-R⁹, -NH-S(=O)₂-R⁹ y/o con un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, y/o con un resto heteroarilo monocíclico con 5 ó 6 átomos de anillo, y/o con un resto fenilo, que a su vez puede estar sustituido dado el caso una o varias veces, de manera igual o diferente, con halógeno, alquilo C₁₋₃ y/o alcoxi C₁₋₃, o representa un resto fenilo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, nitro, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, alquil C₁₋₆-amino-alquilo C₁₋₆, -C(=O)NR⁶R⁷, -C(=O)R⁸, alquil C₁₋₃-sulfinilo, alquil C₁₋₃-sulfonilo, -S(=O)₂NH₂, alquil C₁₋₃-sulfonilamino, alquil C₁₋₃-aminosulfonilo, cicloalquil C₃₋₆-aminosulfonilo, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, hidroxi alquil C₁₋₆, cicloalquilo C₃₋₁₀ y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo y/o un resto heteroarilo monocíclico con 5 ó 6 átomos de anillo, que a su vez dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, alquilo C₁₋₃ y/o alcoxi C₁₋₃, y R¹ᵇ y R¹ᶜ representan, independientemente entre sí, hidrógeno, halógeno, hidroxi, ciano, nitro y/o representa un resto alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, cicloalquilo C₃₋₁₀ y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, y R² representa un resto alquilo C₁₋₃ o trifluorometilo o cicloalquilo C₃ o C₄, y R³ representa ciclopropilo, alquilo C₁₋₃, alcoxi C₁₋₃, amino, ciclopropilamino o alquil C₁₋₃-amino, y R⁴ y R⁵ representan, independientemente entre sí, hidrógeno, hidroxi, ciano, nitro, amino, aminocarbonilo, flúor, cloro, bromo, alquilo C₁₋₆, alcoxi C₁₋₆, alquil C₁₋₆-amino, alquil C₁₋₆-carbonilamino, alquil C₁₋₆-aminocarbonilo o alquil C₁₋₆-aminosulfonilo, o representan alquilo C₁₋₆, alcoxi C₁₋₆, alquil C₁₋₆-amino, alquil C₁₋₆-carbonilamino, alquil C₁₋₆-aminocarbonilo o alquil C₁₋₆-aminosulfonilo que dado el caso pueden estar sustituidos una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, carboxi, hidroxi-alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, heterociclilo monocíclico con 3 a 8 átomos de anillo y/o heteroarilo monocíclico con 5 ó 6 átomos de anillo, pudiendo estar los restos heterociclilo y heteroarilo monocíclicos mencionados a su vez dado el caso sustituidos una vez con alquilo C₁₋₃, o representan cicloalquilo C₃₋₁₀ que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₈, alquil C₁₋₆-amino-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆ y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representan heteroarilo monocíclico con 5 ó 6 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, nitro, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, alquil C₁₋₆-amino-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, cicloalquilo C₃₋₁₀, -C(=O)R⁸, -S(=O)₂R⁹, -NR⁶R⁷ y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representan heterociclilo monocíclico con 3 a 8 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, oxo, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, alquil C₁₋₆-amino-alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, cicloalquilo C₃₋₁₀, -C(=O)R⁸, -S(=O)₂R⁹, -NR⁶R⁷ y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representan fenilo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, nitro, carboxi, alquilo C₁₋₆, alcoxi C₁₋₆, alcoxi C₁₋₆-alquilo C₁₋₆, alquil C₁₋₆-amino, amino-alquilo C₁₋₆, alquil C₁₋₆-aminocarbonilo, alquil C₁₋₆-aminosulfonilo, alquil C₁₋₆-amino-alquilo C₁₋₆, hidroxi-alquilo C₁₋₆, halo-alquilo C₁₋
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012214602 | 2012-08-16 | ||
DE102013202104 | 2013-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092129A1 true AR092129A1 (es) | 2015-03-25 |
Family
ID=48979774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102888A AR092129A1 (es) | 2012-08-16 | 2013-08-14 | 2,3-benzodiazepinas como inhibidoras de proteinas bet |
Country Status (23)
Country | Link |
---|---|
US (1) | US9890147B2 (es) |
EP (1) | EP2885286B1 (es) |
JP (1) | JP6333251B2 (es) |
KR (1) | KR20150041787A (es) |
CN (1) | CN104755473B (es) |
AR (1) | AR092129A1 (es) |
AU (1) | AU2013304146A1 (es) |
CA (1) | CA2881996A1 (es) |
CL (1) | CL2015000337A1 (es) |
CR (1) | CR20150066A (es) |
DO (1) | DOP2015000022A (es) |
EA (1) | EA201590356A1 (es) |
EC (1) | ECSP15005376A (es) |
ES (1) | ES2628005T3 (es) |
HK (1) | HK1208443A1 (es) |
IL (1) | IL236898A0 (es) |
MX (1) | MX2015001880A (es) |
PE (1) | PE20150729A1 (es) |
PH (1) | PH12015500323A1 (es) |
TN (1) | TN2015000051A1 (es) |
TW (1) | TW201408651A (es) |
UY (1) | UY34977A (es) |
WO (1) | WO2014026997A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之***酮化合物 |
KR20150119926A (ko) * | 2013-02-19 | 2015-10-26 | 바이엘 파마 악티엔게젤샤프트 | 비시클로 2,3-벤조디아제핀 및 스피로시클릭 치환된 2,3-벤조디아제핀 |
EP2970282B1 (en) | 2013-03-15 | 2019-08-21 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
WO2015006193A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
WO2015121226A1 (de) * | 2014-02-13 | 2015-08-20 | Bayer Pharma Aktiengesellschaft | 6-substituierte 2,3-benzodiazepine |
PL3134403T3 (pl) | 2014-04-23 | 2020-07-13 | Incyte Corporation | 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET |
ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
AU2015333689A1 (en) | 2014-10-14 | 2017-05-25 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
WO2016062688A1 (de) * | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | 1-phenyl-4,5-dihydro-3h-2,3-benzodiazepine derivatives |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
WO2017005711A1 (de) * | 2015-07-09 | 2017-01-12 | Bayer Pharma Aktiengesellschaft | Phosphor- und schwefel-substituierte benzodiazepin-derivate |
WO2017063959A1 (de) * | 2015-10-15 | 2017-04-20 | Bayer Pharma Aktiengesellschaft | N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
US10167293B2 (en) * | 2016-05-26 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones |
DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
CA3220975A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
SG11201900424SA (en) | 2016-08-15 | 2019-02-27 | Givaudan Sa | Organic compounds |
CN109406685B (zh) * | 2018-12-27 | 2021-05-25 | 湖南泰新医药科技有限公司 | 一种分离卡非佐米和其异构体的高效液相色谱方法 |
WO2020242923A1 (en) * | 2019-05-24 | 2020-12-03 | Emory University | Uses of radiation and benzodiazepine derivatives in cancer therapies |
WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN114920727B (zh) * | 2022-05-26 | 2023-07-25 | 重庆华邦制药有限公司 | 一种卢帕他定的制备方法 |
WO2023229535A1 (en) | 2022-05-27 | 2023-11-30 | Engine Biosciences Pte. Ltd. | Bet polypeptide therapeutic agents for generating synthetic lethality in tumors |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3483186A (en) * | 1966-11-22 | 1969-12-09 | Mcneilab Inc | 2-benzazepine derivatives |
HU208429B (en) | 1991-05-03 | 1993-10-28 | Gyogyszerkutato Intezet | Process for producing 1-/3-chloro-phenyl/-4-methyl-7,8-dimethoxy-5h-2,3-benzodiazepine of high purity |
JP3239364B2 (ja) | 1991-10-11 | 2001-12-17 | ウェルファイド株式会社 | 骨粗鬆症治療薬およびジアゼピン化合物 |
EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
CA2162715A1 (en) | 1993-05-13 | 1994-11-24 | Hideo Tomozane | 3-aminoazepine compound and pharmaceutical use thereof |
DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
HU9600871D0 (en) * | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
PL330635A1 (en) | 1996-06-12 | 1999-05-24 | Japan Tobacco Inc | Inhibitor of cytokin production, triazepin compound and intermediate compounds used for obtaining the last mentioned one |
ES2182108T3 (es) | 1996-09-13 | 2003-03-01 | Mitsubishi Pharma Corp | Compuestos de tienotriazolodiazepina y usos medicinales de los mismos. |
US6887867B2 (en) | 2000-06-16 | 2005-05-03 | Transgenomic, Inc. | 5H-2,3-benzodiazepine antagonists of excitatory amino acid receptors |
HU225100B1 (hu) * | 2000-12-21 | 2006-06-28 | Egyt Gyogyszervegyeszeti Gyar | 2,3-Benzodiazepinszármazékok, ilyen hatóanyagot tartalmazó gyógyászati készítmények és alkalmazásuk |
JP2005532291A (ja) | 2002-04-12 | 2005-10-27 | ファイザー株式会社 | 抗炎症薬および鎮痛薬としてのピラゾール化合物 |
US6858605B2 (en) * | 2003-02-04 | 2005-02-22 | Ivax Drug Research Institute, Ltd. | Substituted 2,3-benzodiazepine derivatives |
GB0425196D0 (en) | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
GB0503962D0 (en) | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
WO2006129623A1 (ja) | 2005-05-30 | 2006-12-07 | Mitsubishi Tanabe Pharma Corporation | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
EA016087B1 (ru) * | 2005-12-30 | 2012-02-28 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Оптические изомеры дигидро-2,3-бензодиазепинов и их стереоселективный синтез |
DE102006042439A1 (de) | 2006-09-09 | 2008-03-27 | Saltigo Gmbh | Verfahren zur katalytischen Herstellung von aromatischen oder heteroaromatischen Nitrilen |
TW200902024A (en) * | 2007-04-02 | 2009-01-16 | Teva Pharma | Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents |
JP2008308491A (ja) * | 2007-05-11 | 2008-12-25 | Gunma Univ | がん治療用の遊走阻害剤 |
EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMOR AGENT |
WO2011037128A1 (ja) * | 2009-09-28 | 2011-03-31 | 日本曹達株式会社 | 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤 |
AU2010314395B2 (en) | 2009-11-05 | 2015-04-09 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP3050885B1 (en) | 2009-11-05 | 2017-10-18 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
ES2534521T3 (es) | 2010-05-14 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades |
WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
-
2013
- 2013-08-13 US US14/421,994 patent/US9890147B2/en not_active Expired - Fee Related
- 2013-08-13 KR KR20157003659A patent/KR20150041787A/ko not_active Application Discontinuation
- 2013-08-13 CN CN201380053739.2A patent/CN104755473B/zh not_active Expired - Fee Related
- 2013-08-13 JP JP2015526970A patent/JP6333251B2/ja not_active Expired - Fee Related
- 2013-08-13 EA EA201590356A patent/EA201590356A1/ru unknown
- 2013-08-13 AU AU2013304146A patent/AU2013304146A1/en not_active Abandoned
- 2013-08-13 PE PE2015000185A patent/PE20150729A1/es not_active Application Discontinuation
- 2013-08-13 CA CA2881996A patent/CA2881996A1/en not_active Abandoned
- 2013-08-13 MX MX2015001880A patent/MX2015001880A/es unknown
- 2013-08-13 EP EP13748072.9A patent/EP2885286B1/de not_active Not-in-force
- 2013-08-13 ES ES13748072T patent/ES2628005T3/es active Active
- 2013-08-13 WO PCT/EP2013/066931 patent/WO2014026997A1/de active Application Filing
- 2013-08-14 AR ARP130102888A patent/AR092129A1/es unknown
- 2013-08-14 UY UY0001034977A patent/UY34977A/es not_active Application Discontinuation
- 2013-08-15 TW TW102129344A patent/TW201408651A/zh unknown
-
2015
- 2015-01-25 IL IL236898A patent/IL236898A0/en unknown
- 2015-02-06 DO DO2015000022A patent/DOP2015000022A/es unknown
- 2015-02-10 CR CR20150066A patent/CR20150066A/es unknown
- 2015-02-12 CL CL2015000337A patent/CL2015000337A1/es unknown
- 2015-02-12 EC ECIEPI20155376A patent/ECSP15005376A/es unknown
- 2015-02-13 PH PH12015500323A patent/PH12015500323A1/en unknown
- 2015-02-13 TN TNP2015000051A patent/TN2015000051A1/fr unknown
- 2015-09-15 HK HK15108988.0A patent/HK1208443A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN104755473B (zh) | 2017-03-08 |
JP2015529192A (ja) | 2015-10-05 |
KR20150041787A (ko) | 2015-04-17 |
ECSP15005376A (es) | 2015-12-31 |
DOP2015000022A (es) | 2015-09-15 |
PE20150729A1 (es) | 2015-06-14 |
CN104755473A (zh) | 2015-07-01 |
IL236898A0 (en) | 2015-03-31 |
UY34977A (es) | 2014-03-31 |
US9890147B2 (en) | 2018-02-13 |
PH12015500323A1 (en) | 2015-03-30 |
EA201590356A1 (ru) | 2015-07-30 |
JP6333251B2 (ja) | 2018-05-30 |
HK1208443A1 (en) | 2016-03-04 |
MX2015001880A (es) | 2015-05-11 |
ES2628005T3 (es) | 2017-08-01 |
AU2013304146A1 (en) | 2015-02-26 |
TW201408651A (zh) | 2014-03-01 |
WO2014026997A1 (de) | 2014-02-20 |
TN2015000051A1 (en) | 2016-06-29 |
EP2885286B1 (de) | 2017-03-22 |
CA2881996A1 (en) | 2014-02-20 |
CR20150066A (es) | 2015-04-17 |
CL2015000337A1 (es) | 2015-05-04 |
EP2885286A1 (de) | 2015-06-24 |
US20150203483A1 (en) | 2015-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092129A1 (es) | 2,3-benzodiazepinas como inhibidoras de proteinas bet | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
CL2018003060A1 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
BR112017012755A2 (pt) | compostos de heteroarila de anel fundido e seu uso como inibidores de trk | |
UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
AR096330A1 (es) | Derivados del bipirazol como inhibidores jak | |
CR20190343A (es) | FORMAS DE DOSIFICACIÓN DE LIBERACIÓN PROLONGADA PARA UN INHIBIDOR DE JAK 1 (Divisional de Exp: 2016-0102) | |
AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
AR106099A1 (es) | Compuestos bicíclicos como inhibidores duales de atx / ca | |
BR112018074268A2 (pt) | pastas dentais terapêuticas e métodos e kits relacionados | |
AR089550A1 (es) | Compuestos quimicos | |
CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
AR089768A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
BR112015019811A2 (pt) | 2,3-benzodiazepinas bicíclicas e 2,3-benzodiazepinas espirocíclicas substituídas | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
BR112015018509A2 (pt) | compostos de imidazo piridina | |
AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
AR111756A1 (es) | 4-difluorometilbenzoilamidas de acción herbicida | |
AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
AR092173A1 (es) | Inhibidores de la syk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |